Global Valsartan Market Size was valued at USD 2.51 Billion by 2035 | CAGR of 5.11%
Category: HealthcareGlobal Valsartan Market Size was valued at USD 2.51 Billion by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Valsartan Market Size is estimated to Grow from USD 1.45 Billion in 2024 to USD 2.51 Billion by 2035, at a CAGR of 5.11% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Valsartan Market Size, Share, and COVID-19 Impact Analysis, By Type (Tablets and Capsules), By Therapeutic Area (Hypertension, Heart Failure, Myocardial Infarction, Diabetic Nephropathy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/valsartan-market
The valsartan market encompasses the worldwide industry for valsartan, an angiotensin II receptor blocker (ARB) primarily used to manage hypertension, heart failure, and other cardiovascular conditions by relaxing blood vessels and lowering blood pressure. Market growth is driven by the rising prevalence of cardiovascular diseases, an aging global population, increasing awareness of heart health, and improvements in healthcare infrastructure in emerging economies. The availability of affordable generic valsartan and innovations in combination therapies and drug delivery further support market expansion. Demand is also fueled by the increasing incidence of lifestyle diseases such as diabetes and obesity, creating a need for long-term, effective blood pressure management solutions, including fixed-dose combination therapies. The valsartan market faces challenges from NDMA contamination, causing recalls, trust issues, and legal actions.
The tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type, the valsartan market is divided into tablets and capsules. Among these, the tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The tablets segment dominated the valsartan market growth due to ease of administration, multiple dosage strengths, patient preference, cost-effectiveness, and wide availability across hospitals, retail, and online pharmacies globally.
The hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the therapeutic area, the valsartan market is divided into hypertension, heart failure, myocardial infarction, diabetic nephropathy, and others. Among these, the hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The hypertension segment accounted for the largest market share due to high global prevalence, chronic treatment requirements, rising cardiovascular disease awareness, and government initiatives promoting long-term blood pressure management.
The retail pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the distribution channel, the valsartan market is divided into hospital pharmacies, retail pharmacies, online pharmacies, drug stores, and others. Among these, the retail pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The retail pharmacies segment market growth is due to wide accessibility, convenience for patients, strong prescription fulfilment, availability of branded and generic valsartan, and expanding pharmacy networks globally.
North America is expected to hold the majority share of the global valsartan market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global valsartan market during the forecast period. North America is anticipated to hold the largest share of the valsartan market due to high prevalence of hypertension and cardiovascular diseases, advanced healthcare infrastructure, strong adoption of prescription medications, widespread availability of branded and generic valsartan, and increasing patient awareness and adherence.
Asia Pacific is anticipated to grow at the fastest pace in the global valsartan market during the forecast period. Asia Pacific is expected to grow in the valsartan market due to rising hypertension prevalence, increasing cardiovascular disease burden, expanding healthcare infrastructure, growing access to affordable generics, and supportive government health initiatives, especially in China and India.
Major vendors in the global valsartan market are Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Hetero Labs Limited, Sun Pharmaceutical Industries, Lupin Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Aurobindo Pharma Limited, Zydus Cadila, Glenmark Pharmaceuticals Inc., AstraZeneca plc, Sandoz International GmbH, Dr Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In July 2024, Zydus Lifesciences Ltd received final USFDA approval to market its generic Sacubitril and Valsartan tablets in strengths 24/26 mg, 49/51 mg, and 97/103 mg. The combination is indicated for treating chronic heart failure in adults, expanding affordable treatment options.
- In January 2023, Glenmark Pharmaceuticals launched Sacu VTM (sacubitril + valsartan tablets) in India for heart failure treatment. Approved for NYHA class II-IV HFrEF patients, the medication reduces cardiovascular deaths and hospitalizations and is prescribed twice daily under medical supervision, enhancing chronic heart failure management.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the valsartan market based on the below-mentioned segments:
Global Valsartan Market, By Type
- Tablets
- Capsules
Global Valsartan Market, By Therapeutic Area
- Hypertension
- Heart Failure
- Myocardial Infarction
- Diabetic Nephropathy
- Others
Global Valsartan Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Others
Global Valsartan Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?